KR20060113729A - Prolinylarylacetamides - Google Patents

Abstract

Novel compounds of formula (I) wherein R, R1, R2, R3, X, X', and Y have the meaning cited in Claim 1. Said compounds are inhibitors of coagulation factor Xa and can be used for the prophylaxis and/or therapy of thromboembolic diseases and in the treatment of tumours.

Description

Prolinylarylacetamide {PROLINYLARYLACETAMIDES}

The present invention relates to compounds of formula I:

(Wherein,

R is Hal, -C≡C-H, -C≡C-A or OA,

R ¹ is H, ═O, Hal, A, OH, OA, A-COO-, Ph- (CH ₂ ) _n -COO-, cycloalkyl- (CH ₂ ) _n -COO-, A-CONH-, A -CONA-, Ph-CONA-, N ₃ , NH ₂ , NO ₂ , CN, COOH, COOA, CONH ₂ , CONHA, CON (A) ₂ , O-allyl, O-propargyl, O-benzyl, = N-OH, = N-OA or = CF ₂ ,

X, X 'are each independently CH, CHal or N,

Y is R ⁴ or Hal,

Ph is phenyl unsubstituted or mono-, di- or trisubstituted with A, OA, OH or Hal,

R ² is H, Hal or A,

R ³ is H or A,

R ⁴ is OH, OA, A-COO-, NHA, NHAr, NAA ', Het or -NH-CHR ⁵ -COOR ³ ,

R ⁵ is H, A, -CHR ³ -OH, (CH ₂ ) _n -Ph, (CH ₂ ) _n -COOH, (CH ₂ ) _n -CONH ₂ , (CH ₂ ) _p -NH ₂ , (CH ₂ ) _n -NH (= NH) NH ₂ , (CH ₂ ) _n -Het ¹ or (CH ₂ ) _n -SR ³ ,

Het is N, O and / or S atoms 1 which may be unsubstituted or mono-, di- or trisubstituted with A, OH, OA, CN, COOH, COOA and / or carbonyl oxygen (= O). Mono-4 or bicyclic saturated, unsaturated or aromatic heterocycle,

Het ¹ is mono- or bicyclic aromatic having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted with A, OH, OA and / or CN. Heterocycle,

A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms may be replaced with F and / or chlorine,

Ar is unsubstituted or Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ , CON (R ³ ) ₂ , NR ³ COA, NR ³ CON (R ³ ) ₂ , NR ³ SO ₂ A, COR ³ , SO ₂ N (R ³ ) ₂ , S (O) _n A,-[C (R ³ ) ₂ ] _n -COOR ³ or -O- [C (R ³ ) ₂ ] _p -COOR ³ is mono-, di- or trisubstituted naphthyl, biphenyl or phenyl,

Hal is F, Cl, Br or I,

n is 0, 1, 2 or 3,

p is 1, 2, 3, 4 or 5)

And pharmaceutically usable derivatives, solvates, salts and stereoisomers and mixtures thereof in all ratios.

The present invention aims to find novel compounds with useful properties, in particular compounds which can be used in the preparation of a medicament.

The compounds of formula (I) and salts thereof have been found to have very useful pharmacological properties and good resistance. In particular, they exhibit factor Xa-inhibiting properties and can be used for the treatment and prevention of thromboembolic diseases such as thrombosis, myocardial infarction, arteriosclerosis, inflammation, stroke, angina, restenosis after angioplasty and intermittent claudication.

The compounds of formula (I) according to the invention may also be inhibitors of the factor VIIa, factor IXa and thrombin, which are coagulation factors in the blood coagulation cascade.

Aromatic amidine derivatives with antithrombotic action are described, for example, in EP 0 540 051 B1, WO 98/28269, WO 00/71508, WO 00/71511, WO 00/71493, WO 00/71507, WO 00/71509, Known from WO 00/71512, WO 00/71515 or WO 00/71516. Cyclic guanidines for the treatment of thromboembolic diseases are described, for example, in WO 97/08165. Aromatic heterocycles having factor Xa-inhibiting activity are for example disclosed in WO 96/10022. Substituted N-[(aminoiminomethyl) phenyl-alkyl] azaheterocyclylamides as Factor Xa inhibitors are described in WO 96/40679.

Other carboxamide derivatives are known from WO 02/48099 and WO 02/57236 and other pyrrolidine derivatives are described in WO 02/100830. Another heterocyclic derivative is known from WO 03/045912. Pyrrolidine derivatives as inhibitors of endothelin converting enzymes are known from WO 02/06222. Pyrrolidine derivatives as cholecystokinin and gastrin inhibitors are described in US Pat. No. 5,340,801. Other pyrrolidine derivatives are known from WO 01/044192.

The antithrombotic and anticoagulant effects of the compounds according to the invention are due to the inhibitory action on the activated coagulation protease, known by the factor VIIa, or the inhibition of other activated serine proteases such as factor VIIa, factor IXa or thrombin.

Factor Xa is one of the proteases involved in the complex process of blood coagulation. Factor Xa catalyzes the conversion of prothrombin to thrombin. Thrombin decomposes fibrinogen into fibrin monomers that make a fundamental contribution to thrombus formation after crosslinking. Activation of thrombin can lead to thromboembolic diseases. However, inhibition of thrombin can inhibit fibrin formation involved in thrombus formation.

Inhibition of thrombin can be measured, for example, by the method of GF Cousins et al. In Circulation 1996 , 94, 1705-1712.

Thus, inhibition of factor Xa can prevent the formation of thrombin. The compounds of formula I and their salts according to the invention participate in the blood coagulation process by inhibiting factor Xa and therefore inhibit the formation of thrombi.

Inhibition of factor Xa and measurement of anticoagulant and antithrombotic activity by the compounds according to the invention can be confirmed by conventional in vitro or in vivo methods. Suitable methods are described, for example, in J. Hauptmann et al. In Thrombosis and Haemostasis 1990 , 63, 220-223.

Inhibition of factor Xa can be measured, for example, by the method of T. Hara et al. In Thromb . Haemostas . 1994 , 71, 314-319.

Coagulation factor VIIa binds to tissue factors and then initiates the exogenous portion of the coagulation cascade and contributes to the activation of factor X to form factor Xa. Thus, inhibition of factor VIIa prevents the formation of factor VIIa, which in turn prevents the formation of thrombin.

Inhibition of factor VIIa and measurement of anticoagulant and antithrombotic activity by the compounds according to the invention can be confirmed by conventional in vitro or in vivo methods. Conventional methods for the determination of factor VIIa inhibition are described, for example, in HF Ronning et al. In Thrombosis Research 1996 , 84, 73-81.

Coagulation factor IXa is produced in the endogenous coagulation cascade and also participates in the activation of factor X to form factor Xa. Thus, inhibition of factor IXa prevents the formation of factor Xa in different ways.

Inhibition of factor IXa and measurement of anticoagulant and antithrombotic activity by the compounds according to the invention can be confirmed by conventional in vitro or in vivo methods. Suitable methods are described, for example, in J. Chang et al. In Journal of Biological Chemistry 1998 , 273, 12089-12094.

The compounds according to the invention can also be used for the treatment of tumors, tumor diseases and / or tumor metastases. The interrelationship between tissue factor TF / Factor VIIa and the development of various forms of cancer is described in T. Tanigchi and N. R. Lemoine in Biomed. Health Res. (2000), 41 (Molecular Pathogenesis of Pancreatic Cancer), 57-59}.

The following documents describe the antitumor activity of TF-VII and Factor Xa inhibitors on various forms of tumors:

K.M. Donnelly et al. in Thromb. Haemost. 1998; 79: 1041-1047;

E.G. Fischer et al. in J. Clin. Invest. 104; 1213-1221 (1999)

B.M. Mueller et al. in J. Clin. Invest. 101; 1372-1378 (1998);

M.E. Bromberg et al. in Thromb. Haemost. 1999; 82; 88-92.

Compounds of formula (I) are based on thrombosis, myocardial infarction, arteriosclerosis, inflammation, stroke, angina, restenosis after angioplasty, intermittent claudication, venous thrombosis, pulmonary embolism, arterial thrombosis, myocardial ischemia, thrombosis, especially in human and animal medicine It can be used as a pharmaceutical active ingredient for the treatment and prevention of thromboembolic diseases such as unstable angina and seizures.

The compounds according to the invention are also used for the treatment or prevention of atherosclerotic diseases such as coronary artery disease, cerebral artery disease or peripheral artery disease.

The compounds are also used in combination with other thrombolytics in the case of myocardial infarction and also for the prevention of thrombolysis, re-obstruction after percutaneous coronary angioplasty (PTCA) and coronary bypass surgery.

The compounds according to the invention are also used for the prevention of rethrombotic formation in precision surgery and also in connection with artificial organs or as anticoagulants in hemodialysis.

The compounds are also used for cleaning catheters and medical aids used in vivo in patients, or as anticoagulants for the preservation of blood, plasma and other blood products in vitro. The compounds according to the invention are also used in diseases in which blood coagulation makes an important contribution to the course of the disease or exhibits the cause of secondary lesions, such as cancer, including metastasis, inflammatory diseases, including arthritis, and diabetes.

The compounds according to the invention are also used for the treatment of migraine (F. Morales-Asin et al., Headache, 40, 2000, 45-47).

They can also be used to treat tinnitus. The use of anticoagulants in the treatment of tinnitus is described in R. Mora et al., In International Tinnitus Journal (2003), 9 (2), 109-111.

In the treatment of such diseases, the compounds according to the invention can also be combined with other thrombolytic active compounds such as, for example, "tissue plasminogen activator" t-PA, modified t-PA, streptokinase or urokinase and the like. Used in combination. The compounds according to the invention are administered simultaneously or before or after the other substances mentioned above.

Particular preference is given to simultaneous administration with aspirin to prevent recurrence of thrombus formation.

The compounds according to the invention are also used in combination with platelet glycoprotein receptor (IIb / IIIa) antagonists which inhibit platelet aggregation.

The present invention provides compounds of formula I and salts thereof, and

a) a compound of formula II:

(Wherein,

R, R ¹ , R ² , X and X 'have the meaning indicated in claim 1)

To the compound of formula III:

(Wherein,

Y and R ³ have the meaning indicated in claim 1)

Or react with

b) a compound of formula IV:

(Wherein,

R, R ¹ , R ² , R ³ , X and X 'have the meaning indicated in claim 1)

To the compound of formula V:

(Wherein,

Y has the meaning indicated in claim 1,

L is Cl, Br, I or a free or reactively functionally modified OH group)

Or react with

c) a compound of formula VI:

(Wherein,

R and R ¹ have the meaning indicated in claim 1,

L is Cl, Br, I or a free or reactively functionally modified OH group)

To the compound of formula VII:

(Wherein,

R ² , R ³ , X, X 'and Y have the meaning indicated in claim 1)

Or react with

And / or

17. A compound of formula (I) and a pharmaceutically usable derivative, solvate, salt thereof according to any one of claims 1 to 16, characterized in that the base or acid of formula (I) is converted to one of its salts. And to a process for the preparation of stereoisomers.

The invention also relates to optically active forms (stereoisomers), enantiomers, racemates, diastereomers and hydrates and solvates of such compounds. The term solvate of the compound is considered to mean an adduct of inert solvent molecules to the compound formed due to its attraction to each other. Solvates are, for example, mono- or dihydrates or alcoholates.

The term pharmaceutically usable derivative is taken to mean, for example, salts of the compounds according to the invention and so-called prodrug compounds.

The term prodrug derivatives is understood to mean compounds of formula (I) which, for example, are modified with alkyl or acyl groups, sugars or oligopeptides and which are rapidly degraded in an organism to give the active compounds according to the invention.

It is also described, for example, in Int. J. Pharm. 115 , 61-67 (1995)}, including biodegradable polymer derivatives of the compounds according to the invention.

The invention also relates to mixtures of compounds of the formula I according to the invention, for example 1: 1, 1: 2, 1: 3, 1: 4, 1: 5, 1:10, 1 of two diastereomers. To a mixture of a ratio of: 100 or 1: 1000. It is particularly preferably a mixture of stereoisomeric compounds.

For all radicals that appear more than once, for example A, their meanings are independent of each other.

Above and below, the radicals or parameters R, R ¹ , R ² , R ³ , X, X 'and Y have the meanings indicated in the formula (I), unless stated otherwise.

A is alkyl, unbranched (linear) or branched and has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 carbon atoms. A is preferably methyl, also ethyl, propyl, isopropyl, butyl, isobutyl, secondary-butyl or tert-butyl, also pentyl, 1-, 2- or 3-methylbutyl, 1,1-, 1, 2- or 2,2-dimethylpropyl, 1-ethylpropyl, hexyl, 1-, 2-, 3- or 4-methylpentyl, 1,1-, 1,2-, 1,3-, 2,2- , 2,3- or 3,3-dimethylbutyl, 1- or 2-ethylbutyl, 1-ethyl-1-methylpropyl, 1-ethyl-2-methylpropyl, 1,1,2- or 1,2, 2-trimethylpropyl, also preferably, for example, trifluoromethyl. A is also cycloalkyl.

Cycloalkyl is preferably cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl.

Thus A is preferably also cyclopentylmethyl, cyclohexylmethyl, A is very particularly preferably alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, preferably methyl, ethyl, propyl, isopropyl, butyl, Isobutyl, secondary-butyl, tert-butyl, pentyl, hexyl, trifluoromethyl, pentafluoroethyl or 1,1,1-trifluoroethyl.

Alkylene is preferably methylene, ethylene, propylene, butylene, pentylene or hexylene, also branched alkylene.

R is preferably Hal or -C≡C-H.

R ¹ is preferably H, ═O (carbonyl oxygen), Hal, A, OH or OA, particularly preferably OH.

R ² is preferably H or Hal.

X is preferably CH or N;

X 'is preferably CH.

R ³ is preferably H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms.

R ⁵ is preferably H or A.

Unsubstituted Het is, for example, 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrroyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3- , 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, also preferably 1,2,3-triazole-1- , -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazole-4 -Or -5-yl, 1,2,4-oxadiazol-3- or -5-yl, 1,3,4-thiadiazol-2- or -5-yl, 1,2,4-thia Diazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5- , 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxazolyl, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7-benz- 2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- Or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-shinolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl, 5 Or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, also preferably 1,3-benzodioxol-5- 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl.

Heterocyclic radicals may be partially or fully hydrogenated.

Thus, unsubstituted Het can also be used, for example, as 2,3-dihydro-2-, -3-, -4- or -5-furyl, 2,5-dihydro-2-, -3-,- 4- or -5-furyl, tetrahydro-2- or -3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2- or -3-thienyl, 2,3-dihydro-1 -, -2-, -3-, -4- or -5-pyrroyl, 2,5-dihydro-l, -2-, -3-, -4- or -5-pyrroyl, 1- , 2- or 3-pyrrolidinyl, tetrahydro-1-, -2- or -4-imidazolyl, 2,3-dihydro-1-, -2-, -3-, -4-, or -5-pyrazolyl, tetrahydro-1-,-3- or -4-pyrazolyl, 1,4-dihydro-1-, -2-, -3- or -4-pyridyl, 1,2, 3,4-tetrahydro-1-, -2-, -3-, -4-, -5- or -6-pyridyl, 1-, 2-, 3- or 4-piperidinyl, 2-, 3- or 4-morpholinyl, tetrahydro-2-,-3-, or -4-pyranyl, 1,4-dioxanyl, 1,3-dioxan-2-,-4- or -5 -Yl, hexahydro-1-, -3- or -4-pyridazinyl, hexahydro-l, -2-, -4- or -5-pyri Midinyl, 1-, 2- or 3-piperazinyl, 1,2,3,4-tetrahydro-1-,-2-,-3-,-4-, -5-, -6-,- 7- or -8-quinolyl, 1,2,3,4-tetrahydro-1-,-2-,-3-,-4-, -5-, -6-, -7- or -8- Isoquinolyl, 2-, 3-, 5-, 6-, 7- or 8-3,4-dihydro-2H-benzo-1,4-oxazinyl, also preferably 2,3-methylenedioxy Phenyl, 3,4-methylenedioxyphenyl, 2,3-ethylenedioxyphenyl, 3,4-ethylenedioxyphenyl, 3,4- (difluoromethylenedioxy) phenyl, 2,3-dihydrobenzo Furan-5- or -6-yl, 2,3- (2-oxomethylenedioxy) phenyl or optionally 3,4-dihydro-2H-1,5-benzodioxepin-6- or -7-yl And also preferably 2,3-dihydrobenzofuranyl or 2,3-dihydro-2-oxofuranyl.

Het is preferably monocyclic saturated, unsaturated or unsubstituted or mono-, di-, or trisubstituted with A, OH and / or OA, preferably having 1-2 N atoms and / or 0 Aromatic heterocycle.

Het is particularly preferably furyl, thienyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, each unsubstituted or mono-, di-, or trisubstituted with A, OH and / or OA, respectively. , Thiazolyl, indolyl, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl.

Het is very particularly preferably imidazolyl, pyridyl, piperidinyl, morpholinyl or piperazinyl, unsubstituted or mono-, di- or trisubstituted, respectively, with A, OH and / or OA.

Unsubstituted Het ¹ is preferably 2- or 3-furyl, 2- or 3-thienyl, 1-, 2- or 3-pyrroyl, 1-, 2-, 4- or 5-imidazolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5-oxazolyl, 3-, 4- or 5-isoxazolyl, 2-, 4- or 5-thiazolyl, 3- , 4- or 5-isothiazolyl, 2-, 3- or 4-pyridyl, 2-, 4-, 5- or 6-pyrimidinyl, also preferably 1,2,3-triazole-1- , -4- or -5-yl, 1,2,4-triazol-1-, -3- or -5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazole-4 -Or -5-yl, 1,2,4-oxadiazole-3- or -5-yl, 1,3,4-thiadiazole-2- or -5-yl, 1,2,4-thia Diazol-3- or -5-yl, 1,2,3-thiadiazol-4- or -5-yl, 3- or 4-pyridazinyl, pyrazinyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 4- or 5-isoindolyl, 1-, 2-, 4- or 5-benzimidazolyl, 1-, 3-, 4-, 5- , 6- or 7-benzopyrazolyl, 2-, 4-, 5-, 6- or 7-benzoxazolyl, 3-, 4-, 5-, 6- or 7-benzisoxane 1, 2-, 4-, 5-, 6- or 7-benzothiazolyl, 2-, 4-, 5-, 6- or 7-benzisothiazolyl, 4-, 5-, 6- or 7- Benz-2,1,3-oxadiazolyl, 2-, 3-, 4-, 5-, 6-, 7- or 8-quinolyl, 1-, 3-, 4-, 5-, 6-, 7- or 8-isoquinolyl, 3-, 4-, 5-, 6-, 7- or 8-shinolinyl, 2-, 4-, 5-, 6-, 7- or 8-quinazolinyl , 5- or 6-quinoxalinyl, 2-, 3-, 5-, 6-, 7- or 8-2H-benzo-1,4-oxazinyl, also preferably 1,3-benzodioxol- 5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4- or -5-yl or 2,1,3-benzoxadiazol-5-yl .

Het ¹ is particularly preferably an unsubstituted mono- or bicyclic aromatic heterocycle having 1 to 2 atoms of N, O and / or S; Very particularly preferably thienyl, furyl, imidazolyl or indolyl.

Ar is for example phenyl, o-, m- or p-tolyl, o-, m- or p-ethylphenyl, o-, m- or p-propylphenyl, o-, m- or p-isopropyl Phenyl, o-, m- or p-tert-butylphenyl, o-, m- or p-hydroxyphenyl, o-, m- or p-nitrophenyl, o-, m- or p-aminophenyl, o-, m- or p- (N-methylamino) phenyl, o-, m- or p- (N-methylaminocarbonyl) -phenyl, o-, m- or p-acetamidophenyl, o- , m- or p-methoxyphenyl, o-, m- or p-ethoxyphenyl, o-, m- or p-ethoxycarbonylphenyl, o-, m- or p- (N, N- Dimethylamino) phenyl, o-, m- or p- (N, N-dimethylaminocarbonyl) phenyl, o-, m- or p- (N-ethylamino) phenyl, o-, m- or p- ( N, N-diethylamino) phenyl, o-, m- or p-fluorophenyl, o-, m- or p-bromophenyl, o-, m- or p-chlorophenyl, o-, m- Or p- (methylsulfonamido) phenyl, o-, m- or p- (methylsulfonyl) phenyl Also preferably 2,3-, 2,4-, 2,5-, 2,6-, 3 , 4- or 3, 5-difluorophenyl, 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5-dichlorophenyl, 2,3-, 2,4-, 2 , 5-, 2,6-, 3,4- or 3,5-dibromophenyl, 2,4- or 2,5-dinitrophenyl, 2,5- or 3,4-dimethoxyphenyl, 3 -Nitro-4-chlorophenyl, 3-amino-4-chloro-, 2-amino-3-chloro-, 2-amino-4-chloro-, 2-amino-5-chloro- or 2-amino-6- Chlorophenyl, 2-nitro-4-N, N-dimethylamino- or 3-nitro-4-N, N-dimethylaminophenyl, 2,3-diaminophenyl, 2,3,4-, 2,3, 5-, 2,3,6-, 2,4,6- or 3,4,5-trichlorophenyl, 2,4,6-trimethoxyphenyl, 2-hydroxy-3,5-dichlorophenyl, p-iodophenyl, 3,6-dichloro-4-aminophenyl, 4-fluoro-3-chlorophenyl, 2-fluoro-4-bromophenyl, 2,5-difluoro-4-bromo Phenyl, 3-bromo-6-methoxyphenyl, 3-chloro-6-methoxyphenyl, 3-chloro-4-acetamidophenyl, 3-fluoro-4-methoxyphenyl, 3-amino-6 -Methylphenyl, 3-chloro-4-acetamido Carbonyl, or 2,5-dimethyl-4-chloro-phenyl; Also unsubstituted naphthyl or biphenyl.

Ar is particularly preferably naphthyl, or un-substituted or mono-, di- or ^{three with} Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ or CON (R ³ ) ₂ . Substituted phenyl. Ar is very particularly preferably phenyl.

Compounds of formula (I) may have one or more chiral centers, and thus various stereoisomeric forms are possible. Formula I includes all these forms.

The present invention therefore relates in particular to compounds of formula (I) in which at least one of said radicals has one of the preferred meanings indicated above. Some preferred groups of compounds are radicals consistent with Formula I and not shown in more detail have the meanings indicated in Formula I, but include the following sub-formulas Ia to Io:

In Formula Ia,

R is Hal or -C≡C-H;

In formula (Ib),

R ¹ is H, ═O, Hal, A, OH or OA;

In formula (Ic),

R ¹ is OH;

In Id,

X is CH or N,

X 'is CH;

In Ie,

R ² is H or Hal;

In If,

R ³ is H or alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms;

In Ig,

Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA;

In Ih,

Het is unsubstituted or mono-, di-, or trisubstituted with A, OH and / or OA, respectively, with furyl, thienyl, pyrroyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indole 1, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl;

In Ii,

Het ¹ is an unsubstituted mono- or bicyclic aromatic heterocycle having 1 to 2 atoms of N, O and / or S,

In Ij,

R ⁵ is H or A;

In Ik,

Ar is naphthyl, or phenyl unsubstituted or mono-, di- or trisubstituted with Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ or CON (R ³ ) ₂ ;

In Il,

Ar is phenyl;

In Im,

R is Hal or -C≡C-H,

R ¹ is OH,

X is CH or N,

X 'is CH,

Y is R ⁴ or Hal,

R ² is H or Hal,

R ³ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R ⁴ is OH, OA, A-COO-, NHA, NHAr, NAA ', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH,

R ⁵ is H or A,

Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA;

A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms may be replaced with F and / or chlorine,

Hal is F, Cl, Br or I,

n is 0, 1, 2 or 3,

p is 1, 2, 3, 4 or 5;

In In,

A compound of formula (la) according to any one of claims 1 to 14:

(Wherein,

R is Hal or -C≡C-H,

R ¹ is OH,

X is CH or N,

X 'is CH,

Y is R ⁴ or Hal,

R ² is H or Hal,

R ³ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R ⁴ is OH, OA, A-COO-, NHA, NAA ', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH,

R ⁵ is H or A,

Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA,

A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms are to be replaced with F and / or chlorine, or F, Cl, Br or I Can,

Hal is F, Cl, Br or I,

n is 0, 1, 2 or 3,

p is 1, 2, 3, 4 or 5),

In Io,

A compound of formula (la) according to any one of claims 1 to 14:

Formula Ia

(Wherein,

R is Hal or -C≡C-H,

R ¹ is OH,

X is CH or N,

X 'is CH,

Y is R ⁴ or Hal,

R ² is H or Hal,

R ³ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms,

R ^{3 '} is methyl,

R ⁴ is OH, OA, A-COO-, NHA, NAA ', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH,

R ⁵ is H or A,

Het is unsubstituted or mono-, di-, or trisubstituted with A, OH and / or OA, respectively, furyl, thienyl, pyrroyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indole 1, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl,

A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms are to be replaced with F and / or chlorine, or F, Cl, Br or I Can,

Hal is F, Cl, Br or I,

n is 0, 1, 2 or 3,

p is 1, 2, 3, 4 or 5)

And pharmaceutically usable derivatives, solvates and stereoisomers thereof and mixtures thereof in all ratios.

Compounds of formula (I) and starting materials for the preparation thereof are also described in the literature (for example, standard workbooks such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart) It is known to the reaction by methods known per se, such as, and prepared precisely under suitable reaction conditions. Modifications known per se but not mentioned in detail herein may also be used.

If desired, the starting material may also be formed in situ such that it does not separate from the reaction mixture but instead immediately converts into a compound of formula (I).

Starting compounds of formula (II), (III), (IV), (V), (VI) and (VII) are generally known.

Compounds of formula (I) are preferably obtained by reacting a compound of formula (II) with a compound of formula (III). The reaction is preferably carried out under Ullmann reaction conditions (Cul, K ₂ CO ₃ , DMSO 130 °), or particularly preferably Buchwald amidation (J. Am. Chem. Soc. 2002 , 121 , 7421).

This reaction is generally carried out in an inert solvent in the presence of an acid binder, preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of an alkali or alkaline earth metal, preferably potassium, sodium, calcium or cesium. It is also advantageous to add organic bases such as triethylamine, dimethylaniline, N, N'-dimethylenediamine, pyridine or quinoline. The reaction time takes several minutes to 14 days, depending on the conditions used, and the reaction temperature is about 0 ° to 150 °, generally 20 ° to 130 °, particularly preferably 60 to 90 °.

Examples of suitable inert solvents include hydrocarbons such as hexane, petroleum ether, benzene, toluene or xylene; Chlorinated hydrocarbons such as trichloroethylene, 1,2-dichloroethane, tetrachloromethane, chloroform or dichloromethane; Alcohols such as methanol, ethanol, isopropanol, n-propanol, n-butanol or tert-butanol; Ethers such as diethyl ether, diisopropyl ether, tetrahydrofuran (THF) or dioxane; Glycol ethers such as ethylene glycol monomethyl or monoethyl ether, ethylene glycol dimethyl ether (diglyme); Ketones such as acetone or butanone; Amides such as acetamide, dimethylacetamide or dimethylformamide (DMF); Nitriles such as acetonitrile; Sulfoxides such as dimethyl sulfoxide (DMSO); Carbon disulfide; Carboxylic acids such as formic acid or acetic acid; Nitro compounds such as nitromethane or nitrobenzene; Esters such as ethyl acetate, or mixtures of these solvents.

Compounds of formula (I) are also preferably obtained by reacting compounds of formula (IV) with compounds of formula (V). In the compounds of formula (V), L is preferably Cl, Br, I or alkylsulfonyloxy (preferably methylsulfonyloxy or trifluoro), for example activated esters, imidazolides or from 1 to 6 carbon atoms. Reactively modified OH groups, such as methylsulfonyloxy) or arylsulfonyloxy (preferably phenyl- or p-tolylsulfonyloxy) having 6 to 10 carbon atoms.

Radicals of this type for the activation of carboxyl groups in common acylation reactions are described in, for example, standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart). It is described.

Activated esters are advantageously formed in situ, for example by adding HOBt or N-hydroxysuccinimide.

This reaction is generally carried out in an inert solvent in the presence of an acid binder, preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of an alkali or alkaline earth metal, preferably potassium, sodium, calcium or cesium. It may be advantageous to add an organic base such as triethylamine, dimethylaniline, pyridine or quinoline, or an excess of the amine component of formula IV. The reaction time takes several minutes to 14 days, depending on the conditions used, and the reaction temperature is about 0 ° to 150 °, generally 20 ° to 130 °. Suitable inert solvents are as mentioned above.

Compounds of formula (I) are also preferably obtained by reacting compounds of formula (VI) with compounds of formula (VII). In the compounds of formula VI, L is preferably Cl, Br, I or, for example, activated esters, imidazolides or alkylsulfonyloxy (preferably methylsulfonyloxy or trifluoro) having 1 to 6 carbon atoms Reactively modified OH groups, such as methylsulfonyloxy) or arylsulfonyloxy (preferably phenyl- or p-tolylsulfonyloxy) having 6 to 10 carbon atoms.

Radicals of this type for the activation of carboxyl groups in common acylation reactions are described in, for example, standard works such as Houben-Weyl, Methoden der organischen Chemie [Methods of Organic Chemistry], Georg-Thieme-Verlag, Stuttgart). It is described.

Activated esters are advantageously formed in situ, for example by adding HOBt or N-hydroxysuccinimide.

This reaction is generally carried out in an inert solvent in the presence of an acid binder, preferably an alkali or alkaline earth metal hydroxide, carbonate or bicarbonate or other salt of a weak acid of an alkali or alkaline earth metal, preferably potassium, sodium, calcium or cesium. It may be advantageous to add an organic base such as triethylamine, dimethylaniline, pyridine or quinoline, or an excess of the amine component of formula VII. The reaction time takes several minutes to 14 days, depending on the conditions used, and the reaction temperature is about 0 ° to 150 °, generally 20 ° to 130 °. Suitable inert solvents are as mentioned above.

Pharmaceutical salts and other forms

The compounds according to the invention can be used in the form of their final non-salts. On the other hand, the present invention also encompasses the use of these compounds in their pharmaceutically acceptable salt forms, which can be derived from various organic and inorganic acids and bases by methods known in the art. Pharmaceutically acceptable salt forms of the compounds of formula I are for the most part prepared by conventional methods. If the compound of formula (I) comprises a carboxyl group, it may be reacted with a suitable base to form one of its suitable salts by obtaining the corresponding base-addition salt. Such bases include, for example, alkali metal hydroxides including potassium hydroxide, sodium hydroxide and lithium hydroxide; Alkaline earth metal hydroxides such as barium hydroxide and calcium hydroxide; Alkali metal alkoxides such as, for example, potassium ethoxide and sodium propoxide; And various organic bases such as piperidine, diethanolamine and N-methyl-glutamine. Also included are aluminum salts of compounds of formula (I). In the case of certain compounds of formula (I), these compounds are pharmaceutically acceptable organic and inorganic acids, for example hydrogen halides such as hydrogen chloride, hydrogen bromide or hydrogen iodide, other inorganic acids such as sulfates, nitrates or phosphates and the like Corresponding salts and alkyl- and monoarylsulfonates such as ethanesulfonate, toluenesulfonate and benzenesulfonate, and acetates, trifluoroacetates, tartrates, maleates, succinates, citrates, benzoates, salicylates Acid-addition salts can be formed by treatment with other organic acids and their corresponding salts, such as silates, ascorbates and the like. Thus, pharmaceutically acceptable acid-addition salts of compounds of formula I include acetates, adipates, alginates, arginates, aspartates, benzoates, benzenesulfonates (vesylates), bisulfates, bisulfates Fight, bromide, butyrate, camphorate, camphorsulfonate, caprylate, chloride, chlorobenzoate, citrate, cyclopentanepropionate, digluconate, dihydrogenphosphate, dinitrobenzoate, Dodecylsulfate, ethanesulfonate, fumarate, galacterate (from mucic acid), galacturonate, glucoheptanoate, gluconate, glutamate, glycerophosphate, he Immunosate, hemisulfate, heptanoate, hexanoate, hipurate, hydrochloride, hydrobro Id, hydroiodide, 2-hydroxyethanesulfonate, iodide, isethionate, isobutyrate, lactate, lactobionate, malate, maleate , Malonate, mandelate, metaphosphate, methanesulfonate, methylbenzoate, monohydro phosphate, 2-naphthalenesulfonate, nicotinate, nitrate, oxalate, oleate, palmoate, pectinate , Persulfate, phenylacetate, 3-phenylpropionate, phosphate, phosphonate, phthalate.

Base salts of the compounds according to the invention also include aluminum, ammonium, calcium, copper, iron (III), iron (II), lithium, magnesium, manganese (III), manganese (II), potassium, sodium and zinc salts. Included, but not limited to. Among the salts, ammonium; Alkali metal salts sodium and potassium, and alkaline earth metal salts calcium and magnesium are preferred. Salts of compounds of formula (I) derived from pharmaceutically acceptable organic non-toxic bases include primary, secondary and tertiary amines, substituted amines (including naturally occurring substituted amines), cyclic amines, and basic ion exchanges. Resins such as arginine, betaine, caffeine, chloroprocaine, choline, N, N'-dibenzylethylenediamine (benzatin), dicyclohexylamine, diethanolamine, diethylamine, 2-diethylamino Ethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydravamin, isopropylamine, lidocaine, lysine, meglumine, N-methyl-D-glucamine, morpholine, piperazine, piperidine, polyamine resin, procaine, purine, theobromine, triethanolamine, triethylamine, trimethylamine, tripropylamine and tris- (hydroxymethyl) Methylamine Salts of (tromethamine) include, but are not limited to.

Compounds of the present invention comprising basic nitrogen-containing groups include (C ₁ -C ₄ ) alkyl halides such as methyl, ethyl, isopropyl and tert-butyl chloride, bromide and iodide; Di (C ₁ -C ₄ ) alkyl sulfates such as dimethyl, diethyl and diamyl sulfates; (C ₁₀ -C ₁₈ ) alkyl halides such as decyl, dodecyl, lauryl, myristyl and stearyl chloride, bromide and iodide; And aryl (C ₁ -C ₄ ) alkyl halides such as benzyl chloride and phenethyl bromide. Both water soluble and fat soluble compounds according to the invention can be prepared using such salts.

Preferred pharmaceutical salts include acetate, trifluoroacetate, besylate, citrate, fumarate, gluconate, hemisuccinate, hipurate, hydrochloride, hydrobromide, isethionate, mandelate, Include, but are not limited to, meglumine, nitrate, oleate, phosphonate, pivalate, sodium phosphate, stearate, sulfate, sulfosalicylate, tartrate, thiomalate, tosylate and tromethamine Do not.

Acid-addition salts of the basic compounds of formula (I) are prepared by contacting the free base form with a sufficient amount of the desired acid to form the salt in a conventional manner. The free base can be regenerated by contacting the salt form with the base and separating the free base in a conventional manner. The free base form differs in some respects from the form of its corresponding salt in respect of certain physical properties, such as solubility in polar solvents; For the purposes of the present invention, the salts also correspond to their respective free base forms.

As noted above, pharmaceutically acceptable base-addition salts of compounds of formula (I) are formed using metals or amines such as alkali metals and alkali metals or organic amines. Preferred metals are sodium, potassium, magnesium and calcium. Preferred organic amines are N, N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methyl-D-glucamine and procaine.

Base-addition salts of acidic compounds according to the invention are prepared by contacting the free acid form with a sufficient amount of the desired base to form the salt in a conventional manner. The free acid is renewable by contacting the salt form with the acid and separating the free acid in conventional manner. The free acid form differs from its corresponding salt form in certain respects with respect to certain physical properties such as solubility in polar solvents; For the purposes of the present invention, the salts also correspond to their respective free acid forms.

If the compounds according to the invention comprise one or more groups capable of forming pharmaceutically acceptable salts of this type, the invention also includes multiple salts. Common multiple salt forms include, but are not limited to, for example, bitartrate, diacetate, difumarate, dimeglumine, diphosphate, disodium and trihydrochloride.

In the context of the above, "pharmaceutically acceptable salts" herein means, in particular, that the form of such salts is improved in the active ingredient compared to the free form of the active ingredient or in the form of any other salt of the active ingredient previously used. It is understood that by providing pharmacokinetics it is meant an active ingredient comprising a compound of formula (I) in one form of its salt. Pharmaceutically acceptable salt forms of the active ingredient may also provide for the first time the desired pharmacodynamic properties not previously present in such active ingredient, even positive for the pharmacodynamics of this active ingredient with respect to its therapeutic efficacy in the body. Can give a positive effect.

The compounds of formula (I) according to the invention may be of chirality due to their molecular structure and therefore can be in various enantiomeric forms. It may therefore exist in racemic or optically active form.

Since the pharmaceutical activity of the racemates or stereoisomers of the compounds according to the invention may differ from one another, it may be preferable to use enantiomers. In this case, even the final or intermediate can be separated into enantiomeric compounds by chemical or physical methods known to those skilled in the art or used as such in synthesis.

In the case of racemic amines, they are reacted with an optically active dissociating agent to form diastereomers from the mixture. Examples of suitable disintegrating agents include R of tartaric acid, diacetyltartaric acid, dibenzoyltartaric acid, mandelic acid, malic acid, lactic acid, suitably N-protected amino acids (e.g., N-benzoylproline or N-benzenesulfonylproline) and Optically active acids such as S-form, or various optically active camphorsulfonic acids. Chromatographic enantiomeric decomposition (eg, with the aid of an optically active dissociating agent (e.g., dinitrobenzoylphenylglycine, cellulose triacetate or other derivatives of carbohydrates or chirally derivatized methacrylate polymers immobilized on silica gel) Chromatographic enantiomer resolution is also advantageous. Suitable eluents for this purpose are, for example, aqueous or alcoholic solvent mixtures such as hexane / isopropanol / acetonitrile in a ratio of 82: 15: 3.

The invention also relates in particular to the use of a compound of formula (I) and / or a physiologically acceptable salt thereof for the manufacture of a medicament (pharmaceutical composition) by nonchemical methods. They may be converted into suitable dosage forms in combination with one or more solid, liquid and / or semi-liquid excipients or adjuvants and, if necessary, in combination with one or more further active ingredients.

The invention also relates to a medicament comprising at least one compound of formula (I) and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, and mixtures thereof in any proportion, and optionally, excipients and / or auxiliaries. will be.

The pharmaceutical composition may be administered in the form of a dosage unit comprising a predetermined amount of active ingredient per dosage unit. Such units comprise, for example, 0.5 mg to 1 g, preferably 1 mg to 700 mg, particularly preferably 5 mg to 100 mg, depending on the condition of treatment, the method of administration and the age, weight and condition of the patient. Or the pharmaceutical composition can be administered in the form of a dosage unit comprising a predetermined amount of active ingredient per dosage unit. Preferred dosage unit compositions are compositions comprising the active ingredient in a daily dose or in part-dosage, or a corresponding fraction thereof, as described above. In addition, pharmaceutical compositions of this type can be prepared using methods generally known in the pharmaceutical art.

The pharmaceutical composition may be in any desired suitable manner, for example oral (including oral or sublingual), rectal, nasal, topical (including oral, sublingual or transdermal), vaginal or parenteral (subcutaneous, intramuscular, intravenous or For intradermal administration). Such compositions can be prepared using any method known in the art of pharmacy, for example by combining the active ingredient with excipient (s) or adjuvant (s).

Pharmaceutical compositions adapted for oral administration include, for example, capsules or tablets; Powder or granules; Solutions or suspensions that are aqueous or non-aqueous liquids; Edible foams or foamed foods; Or in separate units, such as oil-in-water liquid emulsions or water-in-oil liquid emulsions.

Thus, for oral administration, for example in the form of tablets or capsules, the active-component may be combined with oral, non-toxic and pharmaceutically acceptable inert excipients such as, for example, ethanol, glycerol, water and the like. Powders are prepared by grinding the compound to a suitable fine size and mixing it with pharmaceutical excipients that are ground in a similar manner, such as, for example, edible carbohydrates (such as starch or mannitol, etc.). Flavoring agents, preservatives, dispersants and pigments may also be present.

Capsules are prepared by preparing a powder mixture as described above and using this to fill a shaped gelatin shell. Glidants and lubricants in solid form, for example highly dispersible silicic acid, talc, magnesium stearate, calcium stearate or polyethylene glycol, can be added to the powder mixture prior to the filling operation. . In order to enhance the effectiveness of the medicament after ingestion of the capsules, disintegrants or solubilizers such as, for example, agar-agar, calcium carbonate or sodium carbonate may be added.

In addition, if desired or necessary, suitable binders, lubricants and disintegrants and pigments may also be added to the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, sweeteners made from corn, natural and synthetic rubbers such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene Glycols, waxes and the like.

Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride, and the like. Disintegrants include, but are not limited to, starch, methylcellulose, agar, bentonite, xanthan gum, and the like. Tablets are obtained by, for example, preparing a powder mixture, granulating or dry-pressing the mixture, adding a lubricant and a disintegrant, and pressing the whole mixture to obtain a composition. The powder mixture may be used to slow down the degradation of the compound ground in a suitable manner with a diluent or base as described above and optionally with a binder (e.g., carboxymethylcellulose, alginate, gelatin or polyvinyl-pyrrolidone, etc.) Prepared by mixing with an agent (e.g., paraffin, etc.), an absorption promoter (e.g., quaternary salts, etc.) and / or an absorbent (e.g., bentonite, kaolin or dicalcium phosphate, etc.) The powder mixture can be granulated by wetting it with a binder such as, for example, syrup, starch paste, acadia mucus or a solution of cellulose or polymeric material and pressing it through a sieve. As an alternative to granulation, the powder mixture can be passed through a tableting machine to obtain lumps of non-uniform form, which are broken up to form granules. The granules can be lubricated by adding stearic acid, stearate salts, talc or mineral oil to prevent sticking to tablet casting molds. The lubricated mixture is then pressurized to produce tablets. The compounds according to the invention can also be pressurized immediately after combination with free-flowing inert excipients to obtain tablets without granulation or dry-pressing steps. There may be a transparent or opaque protective layer consisting of a shellac sealing layer, a layer of saccharide or polymeric material and a glossy layer of wax. Pigments may be added to these coatings to distinguish between different dosage units.

For example, oral liquids such as solutions, syrups and elixirs can be prepared in dosage unit form such that a given amount comprises a predetermined amount of a compound. Syrups can be prepared by dissolving the compound with a suitable flavoring agent in an aqueous solution, and elixirs are prepared using a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohol and polyoxyethylene sorbitol ethers, such as preservatives, flavor additives such as peppermint oil or natural sweeteners or saccharin, or other artificial sweeteners, etc. may also be added. have.

Dosage unit compositions for oral administration can be encapsulated in microcapsules as necessary. The compositions can also be prepared in a manner that prolongs or delays release, for example by coating or embedding particulate material in polymers, waxes and the like.

The compounds of formula (I), and salts, solvates and physiologically active derivatives thereof, are also in the form of liposome delivery systems such as, for example, small monolamellar vesicles, large monolayer vesicles and multilayer vesicles. May be administered. Liposomes can be formed from various phospholipids such as, for example, cholesterol, stearylamine or phosphatidylcholine.

The compounds of formula (I), their salts, solvates and physiologically acting derivatives may also be delivered using monoclonal antibodies as individual carriers to which the compound molecules are coupled. This compound may also be coupled to a soluble polymer as a targeted pharmaceutical carrier. Such polymers may include polyvinylpyrrolidone, pyran copolymers, polyhydroxypropylmethacrylamidophenols, polyhydroxyethylaspartamidophenols or polyethylene oxide polylysine, substituted with palmitoyl radicals. The compounds also contain, for example, polyacetic acid, poly-epsilon-caprolactone, polyhydroxybutyric acid, polyorthoesters, polyacetals, polydihydroxypyrans, polycyanoacrylates and blocks of crosslinked or amphiphilic hydrogels. It may also be coupled to a class of biodegradable polymers suitable for controlling the release of a medicament, such as a copolymer.

Pharmaceutical compositions adapted for transdermal administration may be administered in independent plasters that extend in intimate contact with the epidermis of the recipient. Thus, for example, the active ingredient can be delivered from the plaster by iontophoresis as described in general terms in Pharmaceutical Research, 3 (6), 318 (1986).

Pharmaceutical compounds adapted for topical administration may be composed of ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

In order to treat the eye or other external tissues such as the mouth and skin, the composition is preferably applied as a topical ointment or cream. For ointment compositions, the active ingredient can be used with paraffin or water-miscible cream bases. Optionally, the active ingredient may be formulated to obtain a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical compositions adapted for topical application to the eye include eye drops in which the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

Pharmaceutical compositions adapted for topical administration in the mouth include tablets, pastilles and mouthwashes.

Pharmaceutical compositions adapted for rectal administration may be administered in the form of suppositories or enemas.

Pharmaceutical compositions made suitable for nasal administration in which the carrier material is a solid, for example, have a particle size in the range of 20-500 microns and are placed in a nasal manner, ie by placing a container containing the powder near the nose. Coarse powder, which is administered by rapid inhalation through the passage of the nose. Compositions suitable for administration by nasal spray or nasal drops using liquids as carrier materials include active-component solutions in water or oil.

Pharmaceutical compositions adapted for inhalation administration include fine particulate dusts or mists that can be generated by various types of pressurized dispensers, including aerosols, nebulizers or insufflators. Included.

Pharmaceutical compositions adapted for vaginal administration can be administered as pessaries, tampons, creams, gels, pastes, foams or spray compositions.

Pharmaceutical compositions adapted for parenteral administration include aqueous and non-aqueous sterile infusion solutions comprising antioxidants, buffers, bacteriostatic agents and solutes, whereby the composition is isotonic with the blood of a therapeutic recipient; And aqueous and non-aqueous sterile suspensions which may include suspending media and thickeners. The compositions may be administered in single-dose or multi-dose containers such as, for example, sealed ampoules and vials, and freeze-dried (freeze) such that only a sterile carrier liquid, for example water, is added immediately before use for infusion purposes. Can be stored in a lyophilised state.

Infusion solutions and suspensions prepared according to the present formulations can be prepared from sterile powders, granules and tablets.

Needless to say, the composition may, in addition to the components specifically mentioned above, include other agents common in the art with respect to certain forms of the composition; Thus, for example, compositions suitable for oral administration may include flavoring agents.

A therapeutically effective amount of a compound of formula (I) is determined by a number of factors including, for example, the age and weight of the animal, the exact condition in which treatment is required, and its severity, the nature of the composition and the method of administration, ultimately the treatment It is determined by the doctor or veterinarian. However, the effective amount of a compound according to the invention generally ranges from 1.0 to 100 mg / kg body weight of the daily beneficiary (mammal), in particular generally from 1 to 10 mg / kg body weight per day. Thus, for 70 kg mature mammals, the daily actual amount is generally from 70 to 700 mg, which amounts to a series of daily doses (e.g. 2, 3, 4, 5 or 6 times, etc.). An effective amount of its salt or solvate or physiologically acting derivative can be determined as an effective amount of the fraction of the compound according to the invention itself.

Compounds of formula (I) and their physiologically acceptable salts include, but are not limited to, thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina, restenosis after angioplasty, intermittent claudication, migraine, tumor, tumor disease and / or tumor metastasis It can be used for the treatment and prevention of thromboembolic diseases.

The invention also relates to a medicament comprising at least one compound of formula (I) and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, mixtures thereof in all proportions, and at least one further medicament active ingredient.

The invention also

(a) an effective amount of a compound of formula (I) and / or pharmaceutically usable derivatives, solvates and stereoisomers and mixtures thereof in all ratios,

And

(b) a set (kit) consisting of an individual package of an effective amount of an additional pharmaceutical active ingredient.

This set includes a suitable container such as a box, individual bottle, bag or ampoule. This set includes, for example, an effective amount of a compound of formula (I), and / or pharmaceutically acceptable derivatives, solvates and stereoisomers thereof, and mixtures thereof in all ratios,

And individual ampoules each containing an effective amount of an additional pharmaceutical active ingredient in dissolved or lyophilized form.

The invention also provides for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina pectoris, restenosis after angioplasty, intermittent claudication, migraine, tumor, tumor disease and / or tumor metastasis,

In combination with one or more additional pharmaceutical active ingredients,

The use of compounds of formula (I) and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof and mixtures thereof in all proportions.

Above and below, all temperatures are given in degrees Celsius. In the examples which follow, "normal reaction finishing" means adding water if necessary, adjusting the pH to 2-10 according to the composition of the final product if necessary, extracting the mixture with ethyl acetate or dichloromethane, and Is separated, the organic phase is dried over sodium sulphate and evaporated, and the product is purified by chromatography and / or crystallization on silica gel. Rf value on silica gel; Eluent: ethyl acetate / methanol 9: 1

Mass Spectrometry (MS): Electron Impact Ionization (EI) M ⁺

Electrospray Ionization (ESI) (M + H) ⁺ (unless otherwise indicated)

Example  One

1-N- (4 -chlorophenyl ) -2-N- {4-[(2- dimethylaminoethanoyl ) methylamino ] -phenyl }-(2R, 4R) -4 -hydroxypyrrolidine- 1 , 2- dicarboxamide ("A1")

100 mg (0.351 mmol) of (2R, 4R) -1- (4-chlorophenylcarbamoyl) -4-hydroxy-proline ( 1 ) and 72.75 mg (0.351 mmol) of N- (4-aminophenyl)- 2-dimethyl-amino-N-methylacetamide (described in US 2436115, 1945) is dissolved in 1 ml of DMF and 62.29 mg (0.351 mmol) of N- (3-dimethylaminopropyl) -N'-ethylcarb Bodyimide hydrochloride is added and the mixture is stirred at RT for 24 h. Usual reaction to give 35 mg (21%) of "A1"; (M + H) ⁺ 475; mp95 °.

Similarly, the following compounds are obtained.

1-N- (4-chlorophenyl) -2-N- {4-[(2- (N-methyl, N-butylamino) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydro Roxypyrrolidine-1,2-dicarboxamide, mp 98 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (morpholin-4-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypy Lolidine-1,2-dicarboxamide ("A1-1"), mp 86 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (4-hydroxypiperidin-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R)- 4-hydroxypyrrolidine-1,2-dicarboxamide ("A1-2"), mp 78 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (2,6-dimethylmorpholin-4-yl) ethanoyl) methylamino] phenyl}-(2R, 4R)- 4-hydroxypyrrolidine-1,2-dicarboxamide, mp 137 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (3-cyclohexylmethylpiperidin-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) 4-hydroxypyrrolidine-1,2-dicarboxamide, mp 104 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (4-diethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrroli Din-1,2-dicarboxamide, mp 86 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (N-methyl, N-ethylamino) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydro Roxypyrrolidine-1,2-dicarboxamide, mp 113 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2- (2-methylimidazol-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) -4 Hydroxypyrrolidine-1,2-dicarboxamide, mp 171 °;

1-N- (4-ethynylphenyl) -2-N- {4-[(2-dimethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide,

1-N- (4-chlorophenyl) -2-N- {2-fluoro-4-[(2- (4-dimethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4- Hydroxypyrrolidine-1,2-dicarboxamide,

1-N- (4-chlorophenyl) -2-N- {5-[(2-dimethylaminoethanoyl) methylamino] pyridin-2-yl}-(2R, 4R) -4-hydroxypyrroli Din-1,2-dicarboxamide.

Example  2

1-N- (4 -chlorophenyl ) -2-N- {4-[(2- acetoxyethanoyl ) methylamino ] phenyl }-(2R, 4R) -4 -hydroxypyrrolidine- 1, 2- dicarboxamide ("A2")

2.1 Suspend 1.146 g (4.025 mmol) of 1 in 10 ml of THF, add 0.995 g (4.025 mmol) of EEDQ (= ethyl 2-ethoxy-1,2-dihydroquinoline-1-carboxylate) The mixture is stirred for 30 min at RT. After addition of 0.8 g (4.027 mmol) of 4-methylaminoaniline (described in J. Org. Chem. 26, 1961, 1394), the reaction mixture is further stirred at RT for 18 h. Normal reaction was completed and thus 300 mg of 1-N- (4-chlorophenyl) -2-N- {4- (N-methylamino) phenyl}-(2R, 4R) -4-hydroxypyrrolidine- 1,2-dicarboxamide ( 2 ) is obtained, (M + H) ⁺ 390.

2.2 240 mg (0.617 mmol) of ( 2 ) was dissolved in 2 ml of DCM, 82.92 μl (0.771 mmol) acetoxyacetyl chloride, 62.23 μl (0.771 mmol) pyridine and 0.977 mg (0.008 mmol) DMAP (= 4 -(Dimethylamino) -pyridine) is added continuously. The mixture is then stirred for 18 h at RT and the usual reaction is completed to give 125 mg (41%) of "A2", MS = 490 (M + H) ⁺ .

Similarly, the following compounds are obtained.

Methyl (2R, 4R) -2-[({[4-({1- [1- (4-chlorophenylcarbamoyl) -4-hydroxypyrrolidin-2-yl] methanoyl} amino) phenyl ] Methylcarbamoyl} methyl) amino] -4-methylpentanoate, mp 86 °

Example  3

1-N- (4 -chlorophenyl ) -2-N- {4-[(2- ethylaminoethanoyl ) methylamino ] phenyl }-(2R, 4R) -4 -hydroxypyrrolidine- 1, 2- dicarboxamide ("A3")

3.1 Preparation of N- (4-aminophenyl) -2-chloro-N-methylacetamide ( 4 )

1.0 g (4.374 mmol) of 2-chloro-N-methyl-N- (4-nitrophenyl) acetamide ( 3 ) (described in Biochem. J. 55, 1953, 839) are dissolved in 25 ml of THF, Hydrogenate at RT with 0.5 g Pt / C (5%)-55.0% water-moisture. Normal reaction was completed to obtain 4 .

3.2 Suspend 1.146 g (4.025 mmol) of 1 in 10 ml of THF and add 0.995 g (4.025 mmol) of EEDQ (= ethyl 2-ethoxy-1,2-dihydroquinoline-1-carboxylate) The mixture is stirred for 30 min at RT. After addition of 0.8 g (4.027 mmol) of 4 , the reaction mixture is further stirred at RT for 18 h. The reaction was completed in this manner and thus 750 mg (40%) of 1-N- (4 -chlorophenyl ) -2-N- {4-[(2 -chloroethanoyl ) methylamino ] phenyl }-(2R, 4R ) -4 -hydroxypyrrolidine- 1,2-dicarboxamide ("A3a") is obtained, (M + H) ⁺ 466.

3.3 250 mg (0.537 mmol) of “A3a” and 406 μl (0.806 mmol) of ethylamine (2M in THF) are dissolved in 2 ml of acetonitrile, 85.4 mg (0.806) of anhydrous sodium carbonate are added and the mixture is 60 ° C. Stir for 5 hours. By the usual reaction, 81 mg (32%) of "A3", (M + H) ⁺ 475; Get mp121 °.

Similarly, the following compounds are obtained.

1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclohexylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 , 2-dicarboxamide, mp 141 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-methylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, mp 145 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-isopropylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 , 2-dicarboxamide, mp 123.5 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-tert-butylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine -1,2-dicarboxamide, mp 137 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclopentylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 , 2-dicarboxamide, mp 130 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclopropylmethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine- 1,2-dicarboxamide, mp 126 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-chloroethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1,2 Chlorine-substituted dicarboxamides ("A3a")

1-N- (4-chlorophenyl) -2-N- {4-[(2-hydroxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, Obtain 2-dicarboxamide.

Example  4

1-N- (4 -chlorophenyl ) -2-N- {4-[(2 -methoxyethanoyl ) methylamino ] phenyl }-(2R, 4R) -4 -hydroxypyrrolidine- 1, 2- dicarboxamide ("A4")

Under argon, 0.05 mmol of CuI (5 mol%), 1.5 mmol of 2-methoxyacetamide and 2.03 mmol of K ₃ PO ₄ are placed in a flask. After addition of 1.0 ml of toluene, 0.1 mmol (10 mol%) of N, N'-dimethylenediamine and 1.0 mmol of 1-N- (4-chlorophenyl) -2-N- {4- iodophenyl }-(2R, 4R) -4-hydroxy-pyrrolidine-1,2-dicarboxamide ( 5 ), (M + H) ⁺ 487 [prepared similar to Example 3.2], and the mixture Stir at 80 ° C. for 12 h. Cooling and normal reaction afford "A4"; (M + H) ⁺ 462; mp84 °.

Similarly, the following compounds are obtained.

1-N- (4-chlorophenyl) -2-N- {4-[(2-ethoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, mp 89 °;

1-N- (4-chlorophenyl) -2-N- {4-[(2-propoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide,

1-N- (4-chlorophenyl) -2-N- {4-[(2-butoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide,

1-N- (4-ethynylphenyl) -2-N- {4-[(2-methoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide,

1-N- (4-chlorophenyl) -2-N- {2-fluoro-4-[(2-methoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypy Lollidine-1,2-dicarboxamide,

1-N- (4-chlorophenyl) -2-N- {5-[(2-methoxyethanoyl) methylamino] pyridin-2-yl}-(2R, 4R) -4-hydroxypyrroli Din-1,2-dicarboxamide.

Pharmacological Data

Affinity for receptors

Compound no. FXa-IC ₅₀ [nM] TF / FVIIa-IC ₅₀ [M] "A1" 37.0 "A1-1" 54.0 100.0 "A1-2" 37.0 46.0 "A2" "A3" 17.0 25.0

The following examples relate to pharmaceutical compositions.

Example  A: for injection Vials

A solution of 100 g of the active ingredient of formula (I) and 5 g of sodium hydrogen phosphate dissolved in 3 l of secondary distilled water was adjusted to pH 6.5 using 2N hydrochloric acid, then sterile filtered, filled into an injection vial, lyophilized under sterile conditions, Seal under sterile conditions. Each injectable vial contains 5 mg of active ingredient.

Example  B: Suppository

A mixture of 20 g of the active ingredient of formula (I) is melted together with 100 g of soya lecithin and 1400 g of cocoa butter, then poured into a mold and cooled. Each suppository contains 20 mg of active compound.

Example  C: Liquid

A solution is prepared by dissolving 1 g of the active ingredient of formula I, 9.38 g of NaH ₂ PO ₄ .2H ₂ O, 28.48 g of Na ₂ HPO ₄ 12H ₂ 0 and 0.1 g of benzalkonium chloride in 940 mL of secondary distilled water. It is adjusted to pH 6.8, the solution is filled with 1 l and sterilized by irradiation. This solution can be used in the form of eye drops.

Example  D: Ointment

500 mg of the active ingredient of formula I are mixed with 99.5 g of petrolatum under aseptic conditions.

Example  E: tablet

A tablet is prepared by pressing a mixture of 1 kg of active ingredient of formula (I), 4 kg of lactose, 1.2 kg of potato starch, 0.2 kg of talc, and 0.1 kg of magnesium stearate in a conventional manner so that each tablet contains 10 mg of active ingredient.

Example  F: Retreat

Similar to Example E, the tablets are compressed and then coated in a conventional manner using a coating consisting of sucrose, potato starch, talc, tragacanth and pigment.

Example  G: Capsule

Hard gelatine capsules are filled with 2 kg of the active ingredient of formula (I) in a conventional manner such that each capsule contains 20 mg of the active ingredient.

Example  H: ampoule

A solution of 1 kg of the active ingredient of formula (I) in 60 liters of secondary distilled water is sterile filtered, filled into ampoules, lyophilized under sterile conditions and sealed under sterile conditions. Each ampoule contains 10 mg of active ingredient.

Claims (24)

Compound of Formula (I): [Formula I]

(Wherein, R is Hal, -C≡C-H, -C≡C-A or OA, R ¹ is H, ═O, Hal, A, OH, OA, A-COO-, Ph- (CH ₂ ) _n -COO-, cycloalkyl- (CH ₂ ) _n -COO-, A-CONH-, A -CONA-, Ph-CONA-, N ₃ , NH ₂ , NO ₂ , CN, COOH, COOA, CONH ₂ , CONHA, CON (A) ₂ , O-allyl, O-propargyl, O-benzyl, = N-OH, = N-OA or = CF ₂ , X, X 'are each independently CH, CHal or N, Y is R ⁴ or Hal, Ph is phenyl unsubstituted or mono-, di- or trisubstituted with A, OA, OH or Hal, R ² is H, Hal or A, R ³ is H or A, R ⁴ is OH, OA, A-COO-, NHA, NHAr, NAA ', Het or -NH-CHR ⁵ -COOR ³ , R ⁵ is H, A, -CHR ³ -OH, (CH ₂ ) _n -Ph, (CH ₂ ) _n -COOH, (CH ₂ ) _n -CONH ₂ , (CH ₂ ) _p -NH ₂ , (CH ₂ ) _n -NH (= NH) NH ₂ , (CH ₂ ) _n -Het ¹ or (CH ₂ ) _n -SR ³ , Het is N, O and / or S atoms 1 which may be unsubstituted or mono-, di- or trisubstituted with A, OH, OA, CN, COOH, COOA and / or carbonyl oxygen (= O). Mono-4 or bicyclic saturated, unsaturated or aromatic heterocycle, Het ¹ is mono- or bicyclic aromatic having 1 to 4 N, O and / or S atoms, which may be unsubstituted or mono-, di- or trisubstituted with A, OH, OA and / or CN. Heterocycle, A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms may be replaced with F and / or chlorine, Ar is unsubstituted or Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ , CON (R ³ ) ₂ , NR ³ COA, NR ³ CON (R ³ ) ₂ , NR ³ SO ₂ A, COR ³ , SO ₂ N (R ³ ) ₂ , S (O) _n A,-[C (R ³ ) ₂ ] _n -COOR ³ or -O- [C (R ³ ) ₂ ] _p -COOR ³ is mono-, di- or trisubstituted naphthyl, biphenyl or phenyl, Hal is F, Cl, Br or I, n is 0, 1, 2 or 3, p is 1, 2, 3, 4 or 5) Phosphorus compounds, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method of claim 1, R is Hal or -C≡C-H, characterized in that And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to claim 1 or 2, R ¹ is H, ═O, Hal, A, OH or OA, characterized in that And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to claim 1, wherein R ¹ is OH, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 4, X is CH or N, X 'is CH, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 5, R ² is H or Hal, characterized in that the compound, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 6, R ³ is H or a compound characterized by having 1, 2, 3, 4, 5 or 6 carbon atoms, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 7, Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA. Compound to be made, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 8, Het is unsubstituted or mono-, di-, or trisubstituted with A, OH and / or OA, respectively, furyl, thienyl, pyrroyl, imidazolyl, pyridyl, pyrimidinyl, pyrazolyl, thiazolyl, indole 1, pyrrolidinyl, piperidinyl, morpholinyl or piperazinyl, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 9, Het ¹ is a compound characterized in that an unsubstituted mono- or bicyclic aromatic heterocycle having 1 to 2 N, O and / or S atoms, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 10, R ⁵ is H or A, characterized in that And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 11, Ar is naphthyl, or phenyl unsubstituted or mono-, di- or trisubstituted by Hal, A, OR ³ , N (R ³ ) ₂ , NO ₂ , CN, COOR ³ or CON (R ³ ) ₂ Characterized by a compound, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 12, Ar is a phenyl compound, And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 13, R is Hal or -C≡C-H, R ¹ is OH, X is CH or N, X 'is CH, Y is R ⁴ or Hal, R ² is H or Hal, R ³ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, R ⁴ is OH, OA, A-COO-, NHA, NHAr, NAA ', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH, R ⁵ is H or A, Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA; A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms may be replaced with F and / or chlorine, Hal is F, Cl, Br or I, n is 0, 1, 2 or 3, p is 1, 2, 3, 4 or 5, characterized in that And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method according to any one of claims 1 to 14, Compound of Formula (Ia): Formula Ia

(Wherein, R is Hal or -C≡C-H, R ¹ is OH, X is CH or N, X 'is CH, Y is R ⁴ or Hal, R ² is H or Hal, R ³ is alkyl having 1, 2, 3, 4, 5 or 6 carbon atoms, R ⁴ is OH, OA, A-COO-, NHA, NAA ', Het, -NH-CHR ⁵ -COOR ³ or -NH-CHR ⁵ -COOH, R ⁵ is H or A, Het is a monocyclic saturated, unsaturated or aromatic heterocycle having 1 to 2 atoms of N and / or O, which may be unsubstituted or mono-, di- or trisubstituted with A, OH and / or OA; A, A 'are each independently of each other unbranched, branched or cyclic alkyl having 1 to 12 carbon atoms, and additionally, 1-7H atoms may be replaced with F and / or chlorine, Hal is F, Cl, Br or I, n is 0, 1, 2 or 3, p is 1, 2, 3, 4 or 5), And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. The method of claim 1, 1-N- (4-chlorophenyl) -2-N- {4-[(2-dimethylaminoethanoyl) methylamino] -phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (N-methyl, N-butylamino) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydro Oxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (morpholin-4-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypy Lollidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (4-hydroxypiperidin-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R)- 4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (2,6-dimethylmorpholin-4-yl) ethanoyl) methylamino] phenyl}-(2R, 4R)- 4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (3-cyclohexylmethylpiperidin-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (4-diethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrroli Dine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (N-methyl, N-ethylamino) ethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydro Oxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2- (2-methylimidazol-1-yl) ethanoyl) methylamino] phenyl}-(2R, 4R) -4 Hydroxypyrrolidine-1,2-dicarboxamide, 1-N- (4-ethynylphenyl) -2-N- {4-[(2-dimethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {2-fluoro-4-[(2- (4-dimethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4- Hydroxypyrrolidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {5-[(2-dimethylaminoethanoyl) methylamino] pyridin-2-yl}-(2R, 4R) -4-hydroxypyrroli Dine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-acetoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, Methyl (2R, 4R) -2-[({[4-({1- [1- (4-chlorophenylcarbamoyl) -4-hydroxypyrrolidin-2-yl] methanoyl} amino) phenyl ] Methylcarbamoyl} methyl) amino] -4-methylpentanoate, 1-N- (4-chlorophenyl) -2-N- {4-[(2-ethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-chloroethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1,2 Dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclohexylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-methylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-isopropylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-tert-butylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine -1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclopentylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-cyclopropylmethylaminoethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine- 1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-hydroxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-methoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-ethoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-propoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {4-[(2-butoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1, 2-dicarboxamide, 1-N- (4-ethynylphenyl) -2-N- {4-[(2-methoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypyrrolidine-1 2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {2-fluoro-4-[(2-methoxyethanoyl) methylamino] phenyl}-(2R, 4R) -4-hydroxypy Lollidine-1,2-dicarboxamide, 1-N- (4-chlorophenyl) -2-N- {5-[(2-methoxyethanoyl) methylamino] pyridin-2-yl}-(2R, 4R) -4-hydroxypyrroli Compounds selected from dean-1,2-dicarboxamides And pharmaceutically usable derivatives, solvates, salts and stereoisomers thereof, and mixtures thereof in all ratios. a) a compound of formula II: [Formula II]

(Wherein, R, R ¹ , R ² , X and X 'have the meaning indicated in claim 1) To the compound of formula III: [Formula III]

(Wherein, Y and R ³ have the meanings indicated in claim 1) Or react with b) a compound of formula IV: [Formula IV]

(Wherein, R, R ¹ , R ² , R ³ , X and X 'have the meaning indicated in claim 1) To the compound of formula V: [Formula V]

(Wherein, Y has the meaning indicated in paragraph 1, L is Cl, Br, I or a free or reactively functionally modified OH group) Or react with c) a compound of formula VI: [Formula VI]

(Wherein, R and R ¹ have the meaning indicated in claim 1, L is Cl, Br, I or a free or reactively functionally modified OH group) To the compound of formula VII: [Formula VII]

(Wherein, R ² , R ³ , X, X 'and Y have the meaning indicated in claim 1) Or react with And / or 17. A compound of formula (I) and a pharmaceutically usable derivative, solvate, salt thereof according to any one of claims 1 to 16, characterized in that the base or acid of formula (I) is converted to one of its salts. And preparation of stereoisomers. 17. A compound of formula I according to any one of claims 1 to 16 as an inhibitor of coagulation factor Xa. 17. A compound of formula I according to any one of claims 1 to 16 as an inhibitor of coagulation factor VIIa. A compound of formula (I) according to any one of claims 1 to 16 and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof, mixtures thereof in all proportions, and optionally excipients and / or auxiliaries. A pharmaceutical comprising. A compound comprising the compound of formula (I) according to any one of claims 1 to 16 and / or pharmaceutically usable derivatives, solvates and stereoisomers and mixtures thereof in all proportions, and at least one further pharmaceutical active ingredient Consisting of drugs. Claim 1 to 16 for the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina, restenosis after angioplasty, intermittent claudication, migraine, tumor, tumor disease and / or tumor metastasis. Use of a compound according to any one of the preceding claims and / or physiologically acceptable salts and solvates thereof. (a) an effective amount of a compound of formula (I) according to any one of claims 1 to 16 and / or pharmaceutically usable derivatives, solvates and stereoisomers and mixtures thereof in any ratio, And (b) A set consisting of an individual package of an effective amount of additional pharmaceutical active ingredient (kit). For the manufacture of a medicament for the treatment of thrombosis, myocardial infarction, atherosclerosis, inflammation, stroke, angina, restenosis after angioplasty, intermittent claudication, migraine, tumor, tumor disease and / or tumor metastasis, In combination with one or more additional pharmaceutical active ingredients, Use of a compound of formula (I) according to any one of claims 1 to 16 and / or pharmaceutically usable derivatives, solvates and stereoisomers thereof and mixtures thereof in any proportion.